Actively Recruiting
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Led by China Medical University Hospital · Updated on 2025-02-19
90
Participants Needed
1
Research Sites
228 weeks
Total Duration
On this page
Sponsors
C
China Medical University Hospital
Lead Sponsor
N
National Science and Technology Council, Taiwan
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.
CONDITIONS
Official Title
NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5 -TR) diagnosis of schizophrenia
- Fulfill the Remission in Schizophrenia Working Group (RSWG) criteria for remission: each of eight items in the Positive and Negative Syndrome Scale (PANSS) scoring 3 or lower for 6 months or longer; baseline total PANSS score 59 or lower
- Are physically healthy and laboratory assessments are clinically insignificant
- Have been keeping a fixed dose of antipsychotics (excluding clozapine) for at least 6 months, with no changes allowed during the 12-week study
- Have sufficient education to communicate effectively and complete study assessments
- Agree to participate and provide written informed consent
You will not qualify if you...
- DSM-5-TR diagnosis of intellectual disability or substance (including alcohol) use disorder
- History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) interfering with the study
- Pregnancy or lactation
- Inability to follow protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Psychiatry, China Medical University Hospital
Taichung, Taiwan
Actively Recruiting
Research Team
H
Hsien-Yuan Lane, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here